Table 2.

Prognostic stratification of stage II and III colorectal cancer patients by clinical parameters and the 7-gene expression classifier ColoGuidePro

Test seriesValidation seriesa
UnivariateMultivariateUnivariateMultivariate
ParameterHRb (95% CI)PcHRb (95% CI)PcHRb (95% CI)PcHRb (95% CI)Pc
Gender (male vs. female)1.3 (0.5–3.3)0.51.3 (0.5–3.5)0.61.1 (0.6–2.0)0.80.9 (0.5–1.7)0.8
Age at diagnosis (≥70 vs. <70 y)0.8 (0.3–1.9)0.60.6 (0.2–2.1)0.50.8 (0.4–1.4)0.41.1 (0.6–2.1)0.8
Tumor stage (III vs. II)1.8 (0.7–4.3)0.21.3 (0.4–4.1)0.72.7 (1.4–5.2)0.0022.6 (1.3–5.4)0.009
Tumor location (right vs. left and rectum)0.3 (0.1–0.9)0.030.4 (0.2–1.2)0.10.8 (0.4–1.4)0.40.8 (0.4–1.4)0.4
MSI (MSI-high vs. MSI-low and MSS)0.2 (0.03–1.4)0.10.4 (0.04–3.1)0.4NANANANA
Adjuvant chemotherapy (yes vs. no)1.1 (0.4–3.0)0.90.6 (0.1–2.6)0.51.5 (0.8–2.7)0.20.9 (0.5–1.8)0.8
ColoGuidePro2.9 (1.1–7.5)0.033.2 (1.1–9.3)0.033.7 (2.0–6.8)<0.0013.1 (1.6–5.8)0.001

Abbreviations: MSI, microsatellite instability; MSS, microsatellite-stable; NA, not available.

  • aGEO accession numbers GSE14333 and GSE17538 (n = 215).

  • bHRs and corresponding 95% CIs from univariate or multivariate Cox proportional hazards analysis as indicated. Event is relapse or death from colorectal cancer within 5 years. Censoring is no event or lost to follow-up within 5 years.

  • cP values from Wald test of predictive potential.